Effects of Mulligan Mobilization With Movement Versus Kinesiotaping and Placebo on Knee Function and Injury -Related Outcomes in Basketball Players (Sport _MWM_RTC)

March 29, 2026 updated by: Selda Sokoli Veizaj, University Aleksander Moisiu Durres

Effects of Mulligan Mobilization With Movement Versus Kinesiotaping and Placebo on Knee Function and Injury -Related Outcomes in Basketball Players: A Parallel -Group Randomized Controlled Trial

This is a randomized RTC study where the KOS-ADLS score of athletes' functionality and the OSTRC score of sports overuse injuries were used as outcomes, which were measured before the start of treatment, 1 hour and 2 weeks after treatment. In this study, 3 forms of intervention were used: Mulligan, Kinesiotaping and placebo in young basketball players with knee injuries.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Study type: Randomized Clinical Trial RTC ,with three intervention groups. Population: young basketball players. The intervention will last 2 weeks. Outcomes: KOS-ADLS; OSTRC. Statistical analysis: Mixed ANOVA

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Albania
    • Tirana
      • Tirana, Tirana, Albania, 1001
        • Sports Club Training facilities

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Male and female basketball players Minimum of 2 years of sports experience Presence of knee injury Active participation in organized sports

Exclusion Criteria:

Previous knee surgery Knee instability Neurological disorders Refusal or contraindication to Mulligan mobilization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Mulligan Mobilization with movement MWM
Participants received MWM in the squot position with tibial glide by a physiotherapist licensed to apply the Mulligan technique. 2 times a week for 2 weeks with a duration of 5min.
Other: Mulligan Mobilization with movement MWM
Participants received the MWM technique in a squat position with a tibial glide by a physiotherapist certified in the mulligan concept twice a week for 2 weeks, the treatment lasted 5 minutes.
Active Comparator: Kinesiotaping
Participants in the kinesiotaping group were applied the same kinesiotaping pattern regardless of injury type, with a frequency of 2 times a week for 2 weeks.
Other: Kinesiotaping
Participants received the same kinesiotaping pattern regardless of injury type twice a week for 2 weeks for 5 minutes.
Placebo Comparator: Placebo
Placebo participants underwent a sham intervention to mimic the treatment without therapeutic effect twice a week for 2 weeks for 5 minutes.
Other: Placebo
Participants received a sham intervention to mimic the treatment without therapeutic effect twice a week for 2 weeks, lasting 5 minutes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
KOS-SAS (ADLS)
Time Frame: Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention
The Activities of Daily Living Scale (ADLS) subscale of the Knee Outcome Survey evaluates symptoms and functional limitations during daily activities. Scores range from 0 to 100, with higher scores indicating better function.
Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overuse Injury Questionnaire - Oslo Sports Trauma Research Center (OSTRC)
Time Frame: Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention
The Oslo Sports Trauma Research Center (OSTRC) Overuse Injury Questionnaire is a validated self-report instrument used to monitor the severity and impact of overuse-related musculoskeletal problems. It evaluates the consequences of knee-related problems on sports participation, training volume, sports performance, and symptom severity. Responses to the four key questions are converted into a severity score ranging from 0 to 100, where higher scores indicate greater symptom severity and functional impairment.
Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Sports Activity Scale (SAS) - Knee Outcome Survey.
Time Frame: Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention
The Sports Activity Scale (SAS) of the Knee Outcome Survey assesses knee symptoms and functional limitations during sports and higher-level activities. The scale ranges from 0 to 100, with higher scores indicating better sports-related knee function.
Baseline (Day 0), 1 hour after intervention, and 2 weeks after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Aleksander Moisiu Durres

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • https://www.consort-statement.org
  • https://doi.org/10.1093/ptj/78.2.115
  • https://doi.org/10.1136/bjsports-2012-091524

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 6, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 27, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 27, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 29, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 3, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 29, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Sport_MWM_RTC_"2026
  • Sport_MWM_RTC (Other Identifier: University Aleksander Moisiu)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The individual participant data (IPD) from this study will not be shared due to ethical and privacy considerations. The study involves minor athletes (under 18 years old), and participant consent does not include data sharing with external researchers. To ensure confidentiality and comply with ethical approvals, the data will remain restricted to the study investigators.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Injuries

Clinical Trials on Mulligan Mobilization with movement MWM

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings